Edgestream Partners L.P. acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,928 shares of the biotechnology company’s stock, valued at approximately $2,129,000.
A number of other institutional investors have also recently added to or reduced their stakes in UTHR. BlackRock Inc. acquired a new stake in United Therapeutics in the second quarter worth $2,868,735,000. Janus Henderson Group PLC lifted its stake in United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the last quarter. Jupiter Topco LLC acquired a new position in shares of United Therapeutics during the second quarter valued at $450,140,000. Bank of New York Mellon Corp acquired a new position in shares of United Therapeutics during the second quarter valued at $159,522,000. Finally, Eversept Partners LP boosted its holdings in shares of United Therapeutics by 4.6% during the first quarter. Eversept Partners LP now owns 264,271 shares of the biotechnology company’s stock valued at $156,707,000 after acquiring an additional 11,679 shares during the period. 94.08% of the stock is currently owned by institutional investors.
United Therapeutics Stock Down 0.8%
Shares of NASDAQ UTHR opened at $554.73 on Friday. The stock has a market cap of $23.63 billion, a P/E ratio of 20.93, a P/E/G ratio of 3.91 and a beta of 0.49. The firm’s 50-day simple moving average is $550.00 and its 200 day simple moving average is $538.90. United Therapeutics Corporation has a fifty-two week low of $455.63 and a fifty-two week high of $614.23.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). The company had revenue of $832.50 million for the quarter, compared to analyst estimates of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the business posted $7.16 EPS. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 25.08 earnings per share for the current fiscal year.
United Therapeutics announced that its board has approved a share buyback program on Thursday, October 22nd that permits the company to buy back $2 billion in outstanding shares. This repurchase authorization permits the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Share repurchase programs are generally a sign that the company’s management believes its stock is undervalued.
Analyst Upgrades and Downgrades
UTHR has been the subject of several recent research reports. Royal Bank Of Canada upped their price target on shares of United Therapeutics from $697.00 to $725.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Leerink Partners lifted their price objective on shares of United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research report on Monday, October 19th. HC Wainwright began coverage on shares of United Therapeutics in a research note on Monday, November 9th. They set a “buy” rating and a $660.00 target price for the company. Jefferies Financial Group restated a “buy” rating and issued a $728.00 target price on shares of United Therapeutics in a research report on Wednesday, October 14th. Finally, Raymond James Financial set a $720.00 target price on shares of United Therapeutics in a research report on Wednesday, November 4th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $676.40.
View Our Latest Research Report on UTHR
Key Headlines Impacting United Therapeutics
Investors following UTHR have been watching these headlines:
- Positive Sentiment: The first clinical UThymoKidney transplant advances United Therapeutics’ effort to develop an additional source of transplantable kidneys. Progress in the trial could support the long-term value of its xenotransplantation program, though clinical and regulatory risks remain. Article: First clinical xenotransplant in EXTEND study
- Neutral Sentiment: One article argues UTHR may be below fair value after the transplant announcement. That is an opinion-based valuation view, not a new financial forecast or clinical result. Article: UTHR may be below fair value
- Negative Sentiment: Recent insider-sale reports may weigh on sentiment: CEO Martine Rothblatt sold 5,410 shares for about $3.13 million, while EVP Paul Mahon sold 8,300 shares for about $4.69 million. Rothblatt retained 324,443 shares after her sale; the transactions alone do not establish a change in the company’s outlook. Article: CEO share sale
Insider Activity
In related news, CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $511.09, for a total transaction of $4,855,355.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $165,819,572.87. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 408,148 shares of company stock valued at $220,922,751 in the last ninety days. Company insiders own 8.60% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Recommended Stories
- Five stocks we like better than United Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
